近期，来自香港大学MMLAB 罗平老师团队和上海交大穆尧老师团队的工作 ——Autobio 正式被 ICLR 2026 接收，并获得了 8-8-6-6 的同行评议分数。AutoBio 是 一个面向数字化生物实验室的机器人仿真系统与基准测试平台。我们通过这篇工作，尝试系统性回答一个关键问题： 当前主流的视觉 - 语言 - 动作（Vision-Language-Action, VLA）模型，是否已经具备在真实生物实验室中执行实验流程的能力？ 论文标题：AutoBio: A Simulation and Benchmark for Robotic Automation in Digital Biology Laboratory 论文链接：https://openreview.net/forum?id=UUE6HEtjhu 论文代码：https://github.com/autobio-bench/AutoBio https://huggingface.co/autobio-bench 一．研究背景：为何生物实验室构成关键挑战 现有 VLA 模型的研究和基准测试多局限于 家庭场景 （如整理餐桌、折叠衣物），缺乏对专业 ...

Core Viewpoint - The article discusses the journey and achievements of Megatech, a unicorn company specializing in robotics automation and AI, which is preparing for its IPO in Hong Kong after raising over 2.7 billion yuan and achieving a valuation of 10.5 billion yuan [4][15][18]. Company Overview - Megatech was founded in June 2016 by three friends with backgrounds in communication and automation, who recognized the potential for automation in the life sciences sector [7][8]. - The company initially focused on developing robotic products but pivoted to providing complete automation solutions for laboratories in 2019 [8][9]. Business Model and Revenue - Megatech's business spans various sectors, including life sciences, chemicals, food service, agriculture, integrated circuits, and new energy, leveraging AI and hardware integration [9][12]. - The company reported nearly 1 billion yuan in revenue for the past year, with a compound annual growth rate of 43% from 2022 to 2024 [10][13]. Financial Performance - Revenue increased from 455 million yuan in 2022 to 930 million yuan in 2024, while gross margin improved from approximately 24% to 29% during the same period [13]. - Despite significant revenue growth, Megatech has faced net losses of approximately 759 million yuan, 742 million yuan, and 780 million yuan from 2022 to 2024 due to high R&D investments and other factors [13]. Funding and Valuation - The company has successfully raised over 2.7 billion yuan across multiple funding rounds, with significant investments from various venture capital firms [16][17]. - Megatech's valuation reached 10.5 billion yuan, with major stakeholders including Innovation Works, which holds a 15.07% share [18][19]. Innovation and R&D - Megatech has invested over 1 billion yuan in R&D since 2022, resulting in over 450 authorized patents and numerous patent applications [12][13]. - The company has developed autonomous intelligent systems for smart laboratories and intelligent manufacturing, addressing specific needs in the market [11][12]. Market Position and Future Outlook - Megatech has established a strong client base, serving over 880 customers, including major companies like Agilent Technologies and WuXi AppTec [13]. - With over 450 million yuan in cash and 1.5 billion yuan in orders, the company is well-positioned for its upcoming IPO [14].

Core Viewpoint - The article highlights the recent completion of nearly 100 million RMB Series A financing by Suzhou Zhongxi Biological Information Co., Ltd. (Zhongxi Bio), aimed at accelerating the development and global promotion of its automated intelligent ecosystem in life sciences [1][5]. Company Overview - Suzhou Zhongxi Biological Information Co., Ltd. was established in 2014 and focuses on automation in life sciences, providing automated equipment and comprehensive solutions for various fields including biopharmaceuticals, clinical diagnostics, public health, food safety, and agricultural breeding [1][3]. - The company is recognized as one of the early enterprises in China to conduct research on liquid handling systems, accumulating extensive R&D experience and technical talent [1]. Business Operations - Zhongxi Bio's main business encompasses automation and solutions in life sciences, biopharmaceuticals, forensics, clinical diagnostics, public health, and food quality and safety [3]. - The company offers high-precision micro-liquid handling platforms, fully automated cup systems, electrophoresis systems, nucleic acid extraction systems, and enzyme-linked detection systems [3]. Financing History - In January 2024, Zhongxi Bio completed a Pre-A+ round of financing led by QM261 Limited, with continued investment from Qiming Venture Partners [4]. - In April 2024, the company secured another Pre-A+ round of financing from Suzhou Sequoia Puxin II Medical Health Industry Investment Partnership, with connections to Sequoia Capital [4]. - The recent Series A financing in July 2025 was led by CITIC Construction Investment, with ongoing investment from Qiming Venture Partners [5].